Tumor angiogenesis: therapeutic implications.
- J. Folkman
- MedicineNew England Journal of Medicine
- 18 November 1971
This new capillary growth is even more vigorous and continuous than a similar outgrowth of capillary sprouts observed in 2016 and is likely to be accompanied by neovascularization.
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
- D. Hanahan, J. Folkman
- ArtCell
- 9 August 1996
Angiogenesis in cancer, vascular, rheumatoid and other disease
- J. Folkman
- Medicine, BiologyNature Network Boston
- 1995
Think of the switch to the angiogenic phenotype as a net balance of positive and negative regulators of blood vessel growth, which may dictate whether a primary tumour grows rapidly or slowly and whether metastases grow at all.
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.
- N. Weidner, J. Semple, W. Welch, J. Folkman
- Medicine, BiologyNew England Journal of Medicine
- 3 January 1991
The number of microvessels per 200x field in the areas of most intensive neovascularization in an invasive breast carcinoma may be an independent predictor of metastatic disease either in axillary lymph nodes or at distant sites (or both).
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth
- M. O'Reilly, T. Boehm, J. Folkman
- BiologyCell
- 24 January 1997
What is the evidence that tumors are angiogenesis dependent?
- J. Folkman
- MedicineJournal of the National Cancer Institute
- 3 January 1990
Method of treating a wound or burn which comprises directly dressing its surface with non-woven fabric comprising staple fibers of spun, regenerated collagen substantially free of telopeptides is…
Angiogenesis: an organizing principle for drug discovery?
- J. Folkman
- Biology, MedicineNature reviews. Drug discovery
- 2007
Viewing the process of angiogenesis as an 'organizing principle' in biology, intriguing insights into the molecular mechanisms of seemingly unrelated phenomena might be gained for the clinical use ofAngiogenesis inhibitors and for drug discovery, for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various diseases that are otherwise unrelated to each other.
Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy.
- P. Hahnfeldt, D. Panigrahy, J. Folkman, L. Hlatky
- BiologyCancer Research
- 1 October 1999
This work poses a quantitative theory for tumor growth under angiogenic stimulator/inhibitor control that is both explanatory and clinically implementable and reveals the existence of an ultimate limitation to tumor size underAngiogenic control.
Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma
- M. O'Reilly, L. Holmgren, J. Folkman
- Biology, MedicineCell
- 21 October 1994
Angiogenic factors.
- J. Folkman, M. Klagsbrun
- BiologyScience
- 1987
In addition to the persistent angiogenesis induced by tumors, it now appears that a variety of nonneoplastic diseases can be considered as "angiogenic diseases" because they are dominated by the pathologic growth of capillary blood vessels.
...
...